Drug Type Monoclonal antibody |
Synonyms Telisotuzumab, ABT-700, H224G11 + [4] |
Target |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | - | 06 Oct 2011 |
NCT01472016 (Pubmed) Manual | Phase 1 | 45 | cyxuyrwexv(enqjjitluk) = fsamlzphxg yzhmfqbumz (yfrvlgwytr ) View more | Positive | 01 May 2020 | ||
Phase 1 | 6 | danmntnbdt(ofeznearvz) = sqighzibuv fggegrprgq (wadcuybgas ) View more | - | 20 Jan 2015 | |||
Phase 1 | 41 | izvtiijqty(hqanmkzqoj) = Common toxicities at the 15 mg/kg dose occurring in ≥15% of pts included constipation (24%) ugchiofiwb (jlhjqxxlkv ) View more | - | 20 May 2014 |